Cătălin Tilişcan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cătălin Tilişcan has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Victoria Aramă
National Institute for Infectious Diseases "Prof. Dr. Matei Balş", Bucharest, Romania
22 shared publications- Victoria Aramă
Faculty of Medicine, Department II, Discipline of Infectious Diseases II, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
17 shared publications Raluca Mihăilescu
MD, PhD, National Institute for Infectious Diseases "Prof.Dr. Matei Balş”, Bucharest, Romania
16 shared publicationsCristina Popescu
National Institute for Infectious Diseases "Prof. Dr. Matei Balş", Bucharest, Romania
14 shared publicationsMihaela Rădulescu
National Institute for Infectious Diseases "Prof. Dr. Matei Balş", Bucharest, Romania
14 shared publications- Ștefan Sorin Aramă
Department of Physiology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
13 shared publications
Latest Publications
- Open Access
Immune Reconstitution Inflammatory Syndrome in People Living with HIV on Antiretroviral Therapy—Insights from a Ten-Year Retrospective Analysis in a Romanian Tertiary Hospital
Background/Objectives: Initiation of effective antiretroviral therapy (ART) in people living with HIV (PLWH) may lead to the development of immune reconstitution inflammatory syndrome (IRIS). Characteristics of unmasking versus paradoxical IRIS, and the impact of ART regimens remain incompletely characterized in real-world cohorts. Methods: We conducted a single-center retrospective analysis of patients diagnosed with IRIS over the period 2015–2025 in a tertiary-care hospital of Infectious Diseases from Bucharest, Romania. Several clinical and biological variables were comparatively analyzed between patients with unmasking versus paradoxical IRIS, and between those receiving integrase strand transfer inhibitors (INSTI)-based versus non-INSTI regimens. Results: A total of 57 PLWH were included. The median time to IRIS onset was 21 days [IQR = 14]. Unmasking IRIS was diagnosed in 43.9% of cases, while 56.1% of patients developed paradoxical IRIS. Median values of CD4+ and CD8+ T-cell count, CD4/CD8 ratio, HIV RNA, fibrinogen and C-reactive protein prior ART and upon IRIS diagnosis did not significantly vary according to the IRIS subtype and the ART regimen. However, trends in clinical manifestations and paraclinical parameters highlight the heterogeneity of IRIS presentations. Paired analyses showed increases in CD4+ and CD8+ T-cell counts, CD4/CD8 ratio, fibrinogen and CRP, and a decline in HIV RNA (all p < 0.01). Mortality due to IRIS-related complications was 14.0% overall (24.0% in unmasking IRIS versus 6.3% in paradoxical IRIS; two-sided Fisher’s exact p = 0.120). INSTI use was not significantly associated with IRIS subtype after adjustment for baseline CD4+ T-cell count and time since HIV diagnosis (aOR 0.54, 95% CI 0.14–2.09). Conclusions: This analysis provides insights into the clinical and biological profiles of IRIS and provides valuable descriptive data in clinical practice. Rapid CD4+ T-cell count recovery and HIV RNA decline in presence of elevated inflammatory biomarkers suggest IRIS, but most immunological and virological parameters did not differ significantly by IRIS subtype or ART regimen. Our findings emphasize IRIS variability in clinical cohorts and the importance of further studies to identify more reliable predictive markers for IRIS.
Open AccessImmune Reconstitution Inflammatory Syndrome in People Living with HIV on Antiretroviral Therapy—Insights from a Ten-Year Retrospective Analysis in a Romanian Tertiary Hospital
Background/Objectives: Initiation of effective antiretroviral therapy (ART) in people living with HIV (PLWH) may lead to the development of immune reconstitution inflammatory syndrome (IRIS). Characteristics of unmasking versus paradoxical IRIS, and the impact of ART regimens remain incompletely characterized in real-world cohorts. Methods: We conducted a single-center retrospective analysis of patients diagnosed with IRIS over the period 2015–2025 in a tertiary-care hospital of Infectious Diseases from Bucharest, Romania. Several clinical and biological variables were comparatively analyzed between patients with unmasking versus paradoxical IRIS, and between those receiving integrase strand transfer inhibitors (INSTI)-based versus non-INSTI regimens. Results: A total of 57 PLWH were included. The median time to IRIS onset was 21 days [IQR = 14]. Unmasking IRIS was diagnosed in 43.9% of cases, while 56.1% of patients developed paradoxical IRIS. Median values of CD4+ and CD8+ T-cell count, CD4/CD8 ratio, HIV RNA, fibrinogen and C-reactive protein prior ART and upon IRIS diagnosis did not significantly vary according to the IRIS subtype and the ART regimen. However, trends in clinical manifestations and paraclinical parameters highlight the heterogeneity of IRIS presentations. Paired analyses showed increases in CD4+ and CD8+ T-cell counts, CD4/CD8 ratio, fibrinogen and CRP, and a decline in HIV RNA (all p < 0.01). Mortality due to IRIS-related complications was 14.0% overall (24.0% in unmasking IRIS versus 6.3% in paradoxical IRIS; two-sided Fisher’s exact p = 0.120). INSTI use was not significantly associated with IRIS subtype after adjustment for baseline CD4+ T-cell count and time since HIV diagnosis (aOR 0.54, 95% CI 0.14–2.09). Conclusions: This analysis provides insights into the clinical and biological profiles of IRIS and provides valuable descriptive data in clinical practice. Rapid CD4+ T-cell count recovery and HIV RNA decline in presence of elevated inflammatory biomarkers suggest IRIS, but most immunological and virological parameters did not differ significantly by IRIS subtype or ART regimen. Our findings emphasize IRIS variability in clinical cohorts and the importance of further studies to identify more reliable predictive markers for IRIS.
- Open Access
- 3 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 979
Acute Infections, Antibiotic Use and Antibiotic-Related Knowledge Among People Living with HIV: A Cross-Sectional Questionnaire-Based Study
Background: Acute infections and antibiotic use remain clinically relevant among people living with HIV (PLWH). This exploratory study assessed self-reported acute infections, usual healthcare contact, antibiotic use, and antibiotic-related knowledge among PLWH. Methods: We conducted a single-center cross-sectional questionnaire-based study among 209 PLWH in Bucharest, Romania (October 2025–March 2026). The questionnaire assessed self-reported acute infections and hospitalizations during the preceding 12 months, usual healthcare contact, antibiotic use, and six knowledge items. Frequent self-reported antibiotic use was defined as use on at least three occasions during the preceding 12 months. Results: At least one self-reported acute infection was reported by 45.5% of participants; 9.6% reported an infection-related hospitalization. The family physician was the most frequently reported usual healthcare contact (55.0%), followed by the infectious diseases physician (31.6%). Among 207 participants with evaluable antibiotic-use data, 22 (10.6%) met the frequent-use definition. In exploratory analyses, knowledge scores were higher among participants with greater educational attainment and those living in urban areas, but showed no clear evidence of an association with frequent self-reported antibiotic use (unadjusted OR per 1-point increase, 1.16; 95% CI 0.88–1.54; p = 0.290). In an exploratory adjusted analysis, self-reported acute infection and suboptimal physician-estimated antiretroviral therapy (ART) adherence were associated with frequent self-reported antibiotic use. Conclusions: Frequent self-reported antibiotic use was associated with reported acute infections and suboptimal physician-estimated ART adherence, whereas there was no clear evidence of an association with antibiotic-related knowledge. This pattern suggests that infectious morbidity and care-related factors may be important correlates of repeated antibiotic use in PLWH and highlights the potential value of coordinated stewardship across HIV and primary care.
- 3 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 979
Open AccessAcute Infections, Antibiotic Use and Antibiotic-Related Knowledge Among People Living with HIV: A Cross-Sectional Questionnaire-Based Study
Background: Acute infections and antibiotic use remain clinically relevant among people living with HIV (PLWH). This exploratory study assessed self-reported acute infections, usual healthcare contact, antibiotic use, and antibiotic-related knowledge among PLWH. Methods: We conducted a single-center cross-sectional questionnaire-based study among 209 PLWH in Bucharest, Romania (October 2025–March 2026). The questionnaire assessed self-reported acute infections and hospitalizations during the preceding 12 months, usual healthcare contact, antibiotic use, and six knowledge items. Frequent self-reported antibiotic use was defined as use on at least three occasions during the preceding 12 months. Results: At least one self-reported acute infection was reported by 45.5% of participants; 9.6% reported an infection-related hospitalization. The family physician was the most frequently reported usual healthcare contact (55.0%), followed by the infectious diseases physician (31.6%). Among 207 participants with evaluable antibiotic-use data, 22 (10.6%) met the frequent-use definition. In exploratory analyses, knowledge scores were higher among participants with greater educational attainment and those living in urban areas, but showed no clear evidence of an association with frequent self-reported antibiotic use (unadjusted OR per 1-point increase, 1.16; 95% CI 0.88–1.54; p = 0.290). In an exploratory adjusted analysis, self-reported acute infection and suboptimal physician-estimated antiretroviral therapy (ART) adherence were associated with frequent self-reported antibiotic use. Conclusions: Frequent self-reported antibiotic use was associated with reported acute infections and suboptimal physician-estimated ART adherence, whereas there was no clear evidence of an association with antibiotic-related knowledge. This pattern suggests that infectious morbidity and care-related factors may be important correlates of repeated antibiotic use in PLWH and highlights the potential value of coordinated stewardship across HIV and primary care.
- Open Access
Vaccination Uptake and Pandemic-Related Healthcare Experiences Among People Living with HIV in Romania: A Cross-Sectional Study
Background: The COVID-19 pandemic exposed major vulnerabilities in healthcare accessibility and may have influenced preventive attitudes among people living with HIV (PLWH). However, the relationship between pandemic-related healthcare experiences and vaccination uptake remains insufficiently understood. Materials: A cross-sectional survey was conducted among 203 adults living with HIV receiving follow-up care in Romania between October 2025 and March 2026. The questionnaire evaluated vaccination uptake, vaccine-related perceptions, healthcare information sources, and pandemic-related experiences. Multivariable logistic regression analysis was performed to identify factors independently associated with vaccination uptake. Results: Only 38.9% of participants reported receiving at least one vaccine within the previous three years. The main barriers to vaccination were perceived lack of necessity, lack of physician recommendation, fear of adverse effects, and lack of trust. Multivariable logistic regression identified positive vaccine-related beliefs (OR = 0.454, 95% CI: 0.235–0.876, p = 0.019) and CD4+ T-cell count above 500 cells/mm3 (OR = 0.448, 95% CI: 0.232–0.867, p = 0.017) as independently associated with lower odds of being non-vaccinated. More than half of participants (52.7%) reported at least one pandemic-related disruption or negative health impact. The pandemic-related negative impact composite was not significantly associated with vaccination status (p = 0.209), whereas confirmed COVID-19 infection was more frequent among vaccinated participants than among non-vaccinated participants (43.0% vs. 28.2%, p = 0.030). Pandemic-related negative impact was associated with a greater demand for physician-provided information (p = 0.011). Conclusions: Pandemic-related healthcare experiences were associated with greater demand for physician-provided preventive information, while confirmed COVID-19 infection was more frequent among vaccinated participants. Positive vaccine-related beliefs and higher CD4+ T-cell counts were independently associated with vaccination uptake, while lack of physician recommendation remained a major barrier to vaccination. These findings emphasize the critical role of physicians in improving vaccination coverage among people living with HIV in the post-pandemic era.
Open AccessVaccination Uptake and Pandemic-Related Healthcare Experiences Among People Living with HIV in Romania: A Cross-Sectional Study
Background: The COVID-19 pandemic exposed major vulnerabilities in healthcare accessibility and may have influenced preventive attitudes among people living with HIV (PLWH). However, the relationship between pandemic-related healthcare experiences and vaccination uptake remains insufficiently understood. Materials: A cross-sectional survey was conducted among 203 adults living with HIV receiving follow-up care in Romania between October 2025 and March 2026. The questionnaire evaluated vaccination uptake, vaccine-related perceptions, healthcare information sources, and pandemic-related experiences. Multivariable logistic regression analysis was performed to identify factors independently associated with vaccination uptake. Results: Only 38.9% of participants reported receiving at least one vaccine within the previous three years. The main barriers to vaccination were perceived lack of necessity, lack of physician recommendation, fear of adverse effects, and lack of trust. Multivariable logistic regression identified positive vaccine-related beliefs (OR = 0.454, 95% CI: 0.235–0.876, p = 0.019) and CD4+ T-cell count above 500 cells/mm3 (OR = 0.448, 95% CI: 0.232–0.867, p = 0.017) as independently associated with lower odds of being non-vaccinated. More than half of participants (52.7%) reported at least one pandemic-related disruption or negative health impact. The pandemic-related negative impact composite was not significantly associated with vaccination status (p = 0.209), whereas confirmed COVID-19 infection was more frequent among vaccinated participants than among non-vaccinated participants (43.0% vs. 28.2%, p = 0.030). Pandemic-related negative impact was associated with a greater demand for physician-provided information (p = 0.011). Conclusions: Pandemic-related healthcare experiences were associated with greater demand for physician-provided preventive information, while confirmed COVID-19 infection was more frequent among vaccinated participants. Positive vaccine-related beliefs and higher CD4+ T-cell counts were independently associated with vaccination uptake, while lack of physician recommendation remained a major barrier to vaccination. These findings emphasize the critical role of physicians in improving vaccination coverage among people living with HIV in the post-pandemic era.
- Open Access
- 8 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1074
Inflammatory and Endothelial Dysfunction Biomarkers Predict Severe COVID-19 in Hospitalized Patients: Development of the CCBR Model
Background: Early identification of patients at risk of severe COVID-19 is critical for timely interventions. We evaluated a biomarker-based risk stratification model, the Composite COVID-19 Biomarker Risk (CCBR) score, integrating age and inflammatory biomarkers (IL-6, PAI-1, LDH, neutrophil-to-lymphocyte ratio [NLR], and ferritin) measured at hospital admission to support early clinical risk assessment. Methods: In this retrospective single-center study, 235 hospitalized COVID-19 patients were classified into non-severe (n = 106) and severe (n = 129) groups. Biomarkers were measured within 24 h of admission. The CCBR score (0–6 points) was constructed by assigning one point to each parameter exceeding predefined cut-off values derived from published clinical thresholds and confirmed using receiver operating characteristic (ROC) curve analysis (Youden’s index). Patients were stratified into three risk categories: low risk (0–1 points), moderate risk (2–3 points), and high risk (4–6 points). Associations between CCBR scores and clinical outcomes, including severe disease, acute respiratory failure, dyspnea, complications, and antibiotic use, were assessed using logistic regression and ROC analyses. Internal validation was performed using split-sample validation and bootstrap resampling. Results: CCBR scores were significantly higher among patients with severe disease (p > 0.001). Each 1-point increase in CCBR was associated with a 6.78-fold increase in the odds of severe disease (OR = 6.78, p < 0.001). ROC analysis demonstrated moderate to good discriminative performance for severe disease (AUC = 0.714) and acute respiratory failure (AUC = 0.751). Conclusions: The CCBR score represents a simple biomarker-based model integrating inflammatory and endothelial dysfunction markers for early stratification of COVID-19 severity. This approach may assist clinicians in identifying patients at higher risk of severe disease and acute respiratory failure early during hospitalization.
- 8 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1074
Open AccessInflammatory and Endothelial Dysfunction Biomarkers Predict Severe COVID-19 in Hospitalized Patients: Development of the CCBR Model
Background: Early identification of patients at risk of severe COVID-19 is critical for timely interventions. We evaluated a biomarker-based risk stratification model, the Composite COVID-19 Biomarker Risk (CCBR) score, integrating age and inflammatory biomarkers (IL-6, PAI-1, LDH, neutrophil-to-lymphocyte ratio [NLR], and ferritin) measured at hospital admission to support early clinical risk assessment. Methods: In this retrospective single-center study, 235 hospitalized COVID-19 patients were classified into non-severe (n = 106) and severe (n = 129) groups. Biomarkers were measured within 24 h of admission. The CCBR score (0–6 points) was constructed by assigning one point to each parameter exceeding predefined cut-off values derived from published clinical thresholds and confirmed using receiver operating characteristic (ROC) curve analysis (Youden’s index). Patients were stratified into three risk categories: low risk (0–1 points), moderate risk (2–3 points), and high risk (4–6 points). Associations between CCBR scores and clinical outcomes, including severe disease, acute respiratory failure, dyspnea, complications, and antibiotic use, were assessed using logistic regression and ROC analyses. Internal validation was performed using split-sample validation and bootstrap resampling. Results: CCBR scores were significantly higher among patients with severe disease (p > 0.001). Each 1-point increase in CCBR was associated with a 6.78-fold increase in the odds of severe disease (OR = 6.78, p < 0.001). ROC analysis demonstrated moderate to good discriminative performance for severe disease (AUC = 0.714) and acute respiratory failure (AUC = 0.751). Conclusions: The CCBR score represents a simple biomarker-based model integrating inflammatory and endothelial dysfunction markers for early stratification of COVID-19 severity. This approach may assist clinicians in identifying patients at higher risk of severe disease and acute respiratory failure early during hospitalization.
- Open Access
- 28 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2288
Circulating Liver-Enriched miR-122 in COVID-19 Patients: A Longitudinal Real-Life Study
Abnormal liver function tests are frequently reported in patients with COVID-19. This study aimed to identify potential treatment-associated hepatocellular injury in COVID-19 patients by dynamically assessing circulating miR-122, a biomarker with high hepatic specificity and sensitivity. An exploratory approach was additionally used, given the limited evidence regarding factors influencing miR-122 expression in this setting. We performed a prospective cohort study including 96 adult participants enrolled at a tertiary hospital in Bucharest, Romania, between March 2022 and July 2023: 78 COVID-19 patients (57 with baseline and follow-up miR-122 assessment after 5 days of treatment and 21 with a single measurement) and 18 non-COVID-19 participants included for comparison. Plasma miR-122 levels were measured using quantitative polymerase chain reaction, normalized to U6 small nuclear RNA, and expressed as log10(2−ΔCt). No associations were observed between miR-122 expression and remdesivir administered for standard treatment durations (3–5 days) or other COVID-19–specific therapies. However, a duration-dependent relationship with remdesivir cannot be excluded. Moreover, therapeutic paracetamol use prior to presentation was positively associated with miR-122 expression at follow-up and remained significant after adjustment. Additionally, bivariate analyses revealed inverse correlations between baseline miR-122 and inflammatory biomarkers, with multivariable analysis showing an independent positive association with lymphocyte count.
- 28 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2288
Open AccessCirculating Liver-Enriched miR-122 in COVID-19 Patients: A Longitudinal Real-Life Study
Abnormal liver function tests are frequently reported in patients with COVID-19. This study aimed to identify potential treatment-associated hepatocellular injury in COVID-19 patients by dynamically assessing circulating miR-122, a biomarker with high hepatic specificity and sensitivity. An exploratory approach was additionally used, given the limited evidence regarding factors influencing miR-122 expression in this setting. We performed a prospective cohort study including 96 adult participants enrolled at a tertiary hospital in Bucharest, Romania, between March 2022 and July 2023: 78 COVID-19 patients (57 with baseline and follow-up miR-122 assessment after 5 days of treatment and 21 with a single measurement) and 18 non-COVID-19 participants included for comparison. Plasma miR-122 levels were measured using quantitative polymerase chain reaction, normalized to U6 small nuclear RNA, and expressed as log10(2−ΔCt). No associations were observed between miR-122 expression and remdesivir administered for standard treatment durations (3–5 days) or other COVID-19–specific therapies. However, a duration-dependent relationship with remdesivir cannot be excluded. Moreover, therapeutic paracetamol use prior to presentation was positively associated with miR-122 expression at follow-up and remained significant after adjustment. Additionally, bivariate analyses revealed inverse correlations between baseline miR-122 and inflammatory biomarkers, with multivariable analysis showing an independent positive association with lymphocyte count.
- Open Access
- 9 January 2026
- Published by MDPI AG in Infectious Disease Reports
- Vol. 18 (1) , 9
Human Immunodeficiency Virus Infection in Romania Versus Europe: An Epidemiological and Public Health Perspective, 2024 Update
Background/Objectives: This study presents a comprehensive and updated epidemiological and public health assessment of human immunodeficiency virus (HIV) in Romania during 2022–2024, situated within the wider European context. Methods: For this retrospective descriptive study, we analyzed national surveillance data from the National Institute of Infectious Diseases “Prof. Dr. Matei Balș” and European Centre for Disease Prevention and Control (ECDC) reports, between 1985–2024, focusing especially on 2022–2024 period. Key indicators included incidence, mortality, transmission routes, age and gender distribution, and treatment coverage. Comparative analyses were performed between Romania and European Union (EU)/Eastern Europe data. Results: Between 1985 and 2024, Romania registered a cumulative total of 28,793 HIV cases, with 18,768 individuals living with HIV (PLHIV) as of 2024. In that year, 810 new HIV cases were diagnoses, indicating a modest uptick compared with 2022–2023. Heterosexual transmission continued to predominate (59.4%), followed by cases among men who have sex with men (MSM) (30.5%) and intravenous drug users (IDUs) (5.2%). Men represented more than three-quarters of all new infections. Mortality displayed considerable year-to-year variability, increasing from 125 HIV-related deaths in 2023 to 193 in 2024. Despite this, treatment coverage improved steadily, with 16,464 individuals receiving antiretroviral therapy (ART) by the end of 2024. At 2.51 cases per 100,000 population, Romania’s incidence remained below the European average of 3.5 per 100,000. Nonetheless, the proportion of infections attributable to MSM transmission rose sharply—from 3.91% in 2007 to 32% in 2024—bringing Romania’s epidemiological profile increasingly in line with broader trends observed in Eastern Europe. Conclusions: These findings suggest that although Romania maintains a comparatively lower HIV incidence than the European average, the evolving transmission dynamics—most notably the substantial increase in MSM-related cases—signal a shifting epidemiological landscape that warrants strengthened, population-specific prevention measures and continued investment in comprehensive treatment and monitoring frameworks.
- 9 January 2026
- Published by MDPI AG in Infectious Disease Reports
- Vol. 18 (1) , 9
Open AccessHuman Immunodeficiency Virus Infection in Romania Versus Europe: An Epidemiological and Public Health Perspective, 2024 Update
Background/Objectives: This study presents a comprehensive and updated epidemiological and public health assessment of human immunodeficiency virus (HIV) in Romania during 2022–2024, situated within the wider European context. Methods: For this retrospective descriptive study, we analyzed national surveillance data from the National Institute of Infectious Diseases “Prof. Dr. Matei Balș” and European Centre for Disease Prevention and Control (ECDC) reports, between 1985–2024, focusing especially on 2022–2024 period. Key indicators included incidence, mortality, transmission routes, age and gender distribution, and treatment coverage. Comparative analyses were performed between Romania and European Union (EU)/Eastern Europe data. Results: Between 1985 and 2024, Romania registered a cumulative total of 28,793 HIV cases, with 18,768 individuals living with HIV (PLHIV) as of 2024. In that year, 810 new HIV cases were diagnoses, indicating a modest uptick compared with 2022–2023. Heterosexual transmission continued to predominate (59.4%), followed by cases among men who have sex with men (MSM) (30.5%) and intravenous drug users (IDUs) (5.2%). Men represented more than three-quarters of all new infections. Mortality displayed considerable year-to-year variability, increasing from 125 HIV-related deaths in 2023 to 193 in 2024. Despite this, treatment coverage improved steadily, with 16,464 individuals receiving antiretroviral therapy (ART) by the end of 2024. At 2.51 cases per 100,000 population, Romania’s incidence remained below the European average of 3.5 per 100,000. Nonetheless, the proportion of infections attributable to MSM transmission rose sharply—from 3.91% in 2007 to 32% in 2024—bringing Romania’s epidemiological profile increasingly in line with broader trends observed in Eastern Europe. Conclusions: These findings suggest that although Romania maintains a comparatively lower HIV incidence than the European average, the evolving transmission dynamics—most notably the substantial increase in MSM-related cases—signal a shifting epidemiological landscape that warrants strengthened, population-specific prevention measures and continued investment in comprehensive treatment and monitoring frameworks.
- Open Access
Maternal Antiretroviral Use and the Risk of Prematurity and Low Birth Weight in Perinatally HIV-Exposed Children—7 Years’ Experience in Two Romanian Centers
Background and Objectives: Antiretroviral therapy used during pregnancy in HIV infected women effectively reduces vertical transmission, though concerns about potential adverse newborn outcomes persists. This study focused on prematurity and low birth weight in antiretroviral HIV-exposed children in two major Romanian centers, Bucharest and Constanța, in the context of free access to antiretroviral treatment for pregnant women in Romania since 2001. Materials and Methods: A retrospective observational study was performed including couples of HIV-infected women and their live singleton newborns from 2006 and 2012. Preterm delivery was defined as birth before week 37 and low birth weight was defined as birth weight less than 2500 g in full-term babies. Results: A total number of 352 children and 313 women were enrolled. Mean maternal age at delivery was 23.1 years. Mean newborn birth weight was 2726 g. In the children group, 191 (54.2%) were boys, and the rate of HIV transmission was 13.9%. The prematurity rate was 21.5% and low birth weight rate was 25.56%. Preterm birth was associated with high HIV RNA in the third trimester, HIV-positive final status in infants, and vaginal delivery. Low birth weight was associated with lack of antiretroviral treatment during pregnancy and HIV-positive status in infants. No association was found between prematurity and low birth weight in full-term newborns and exposure to any antiretroviral class, any specific antiviral drug, or with any number of maternal regimens, duration of antiretroviral treatment prior to conception, or maternal exposure during puberty. Conclusions: In our study, preterm birth was significantly associated with HIV vertical transmission in newborns and with exposure to high maternal viral replication during the last trimester of pregnancy. Low birth weight in full-term babies was significantly associated with lack of antiretroviral exposure in utero in our analysis.
Open AccessMaternal Antiretroviral Use and the Risk of Prematurity and Low Birth Weight in Perinatally HIV-Exposed Children—7 Years’ Experience in Two Romanian Centers
Background and Objectives: Antiretroviral therapy used during pregnancy in HIV infected women effectively reduces vertical transmission, though concerns about potential adverse newborn outcomes persists. This study focused on prematurity and low birth weight in antiretroviral HIV-exposed children in two major Romanian centers, Bucharest and Constanța, in the context of free access to antiretroviral treatment for pregnant women in Romania since 2001. Materials and Methods: A retrospective observational study was performed including couples of HIV-infected women and their live singleton newborns from 2006 and 2012. Preterm delivery was defined as birth before week 37 and low birth weight was defined as birth weight less than 2500 g in full-term babies. Results: A total number of 352 children and 313 women were enrolled. Mean maternal age at delivery was 23.1 years. Mean newborn birth weight was 2726 g. In the children group, 191 (54.2%) were boys, and the rate of HIV transmission was 13.9%. The prematurity rate was 21.5% and low birth weight rate was 25.56%. Preterm birth was associated with high HIV RNA in the third trimester, HIV-positive final status in infants, and vaginal delivery. Low birth weight was associated with lack of antiretroviral treatment during pregnancy and HIV-positive status in infants. No association was found between prematurity and low birth weight in full-term newborns and exposure to any antiretroviral class, any specific antiviral drug, or with any number of maternal regimens, duration of antiretroviral treatment prior to conception, or maternal exposure during puberty. Conclusions: In our study, preterm birth was significantly associated with HIV vertical transmission in newborns and with exposure to high maternal viral replication during the last trimester of pregnancy. Low birth weight in full-term babies was significantly associated with lack of antiretroviral exposure in utero in our analysis.
- Open Access
- 10 December 2025
- Published by MDPI AG in Preprints.org
Maternal Antiretroviral Use and the Risk of Prematurity and Low Birth Weight in Perinatally HIV-Exposed Children – 7 Years’ Experience in Two Romanian Centers
Background and Objectives: In the context of free access to antiretroviral treatment for pregnant women in Romania since 2001 and the proven efficacy in vertical transmission of HIV, the impact on newborns exposed to HIV and antiretroviral drugs is concerning. The study focused on prematurity and low birth weight in antiretroviral HIV exposed children in two major Romanian centers, Bucharest and Constanța. Materials and Methods: A retrospective observational study was performed including couples of HIV infected women and their live singleton newborns from 2006 and 2012. Preterm delivery was defined as birth before week 37 and low birth weight was defined as birth weight less than 2500g. Results: The total number 352 children and 313 women were enrolled. Mean maternal age at delivery was 23.1 years. Mean newborns birth weight was 2726g. In the children group 191 (54.2%) were boys and the rate of HIV transmission was 13.9%.The prematurity rate was 21.5% and low birth rate was 25.56%. Preterm birth was associated with high HIV RNA in the third trimester, and HIV positive final status in infants and vaginal delivery. Low birth weight was associated with lack of antiretroviral treatment during pregnancy and HIV positive status in infants. Prematurity and low birth weight were not associated with antiretroviral class, any specific antiviral drug, maternal number of regimens or duration of antiretroviral treatment prior conception, nor with maternal exposure during puberty. Conclusions: Prematurity rate was higher in HIV vertically infected newborns and those exposed to high level of maternal viral replication during the last trimester of pregnancy. Low birth weight rate was associated with lack of in utero antiretroviral exposure. Prematurity and low birth weight were not associated with any antiretroviral class or specific antiretroviral drug, duration and number of regimens before conception or with maternal exposure during childhood and puberty.
- 10 December 2025
- Published by MDPI AG in Preprints.org
Open AccessMaternal Antiretroviral Use and the Risk of Prematurity and Low Birth Weight in Perinatally HIV-Exposed Children – 7 Years’ Experience in Two Romanian Centers
Background and Objectives: In the context of free access to antiretroviral treatment for pregnant women in Romania since 2001 and the proven efficacy in vertical transmission of HIV, the impact on newborns exposed to HIV and antiretroviral drugs is concerning. The study focused on prematurity and low birth weight in antiretroviral HIV exposed children in two major Romanian centers, Bucharest and Constanța. Materials and Methods: A retrospective observational study was performed including couples of HIV infected women and their live singleton newborns from 2006 and 2012. Preterm delivery was defined as birth before week 37 and low birth weight was defined as birth weight less than 2500g. Results: The total number 352 children and 313 women were enrolled. Mean maternal age at delivery was 23.1 years. Mean newborns birth weight was 2726g. In the children group 191 (54.2%) were boys and the rate of HIV transmission was 13.9%.The prematurity rate was 21.5% and low birth rate was 25.56%. Preterm birth was associated with high HIV RNA in the third trimester, and HIV positive final status in infants and vaginal delivery. Low birth weight was associated with lack of antiretroviral treatment during pregnancy and HIV positive status in infants. Prematurity and low birth weight were not associated with antiretroviral class, any specific antiviral drug, maternal number of regimens or duration of antiretroviral treatment prior conception, nor with maternal exposure during puberty. Conclusions: Prematurity rate was higher in HIV vertically infected newborns and those exposed to high level of maternal viral replication during the last trimester of pregnancy. Low birth weight rate was associated with lack of in utero antiretroviral exposure. Prematurity and low birth weight were not associated with any antiretroviral class or specific antiretroviral drug, duration and number of regimens before conception or with maternal exposure during childhood and puberty.
- Top Cited PapersOpen Access
Decoding Inflammation: The Role of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Predicting Critical Outcomes in COVID-19 Patients
Background and Objectives: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are novel biomarkers that provide insight into systemic inflammation and how the immune system responds to stress or infection. These ratios have been associated with predicting clinical outcomes in various diseases, including COVID-19. This study aims to evaluate the prognostic value of NLR and PLR in anticipating ICU admission, acute respiratory failure, and disease severity in COVID-19 patients. Materials and Methods: We conducted a retrospective, observational study that included 536 patients diagnosed with COVID-19. We analyzed the NLR and PLR values at admission and correlated them with ICU admission, the onset of acute respiratory failure, and clinical outcomes. Results: Statistical correlations were identified between elevated NLR and PLR values and the development of complications during hospitalization (p = 0.04 and p = 0.00), acute hypoxemic respiratory failure (p = 0.00), and admission to the intensive care unit (ICU) (p = 0.04). No correlations were found between the values of these ratios and mortality (p = 0.46 and p = 0.32) nor with the development of hepatic cytolysis (p = 0.79 and p = 0.87). Conclusions: NLR and PLR are reliable, easily obtainable biomarkers that can aid in the early prediction of ICU admission and disease severity in COVID-19 patients, offering valuable insights for risk stratification and clinical management. Further prospective studies are needed to validate these biomarkers as part of a broader predictive model for critical care in COVID-19.
Top Cited PapersOpen AccessDecoding Inflammation: The Role of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Predicting Critical Outcomes in COVID-19 Patients
Background and Objectives: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are novel biomarkers that provide insight into systemic inflammation and how the immune system responds to stress or infection. These ratios have been associated with predicting clinical outcomes in various diseases, including COVID-19. This study aims to evaluate the prognostic value of NLR and PLR in anticipating ICU admission, acute respiratory failure, and disease severity in COVID-19 patients. Materials and Methods: We conducted a retrospective, observational study that included 536 patients diagnosed with COVID-19. We analyzed the NLR and PLR values at admission and correlated them with ICU admission, the onset of acute respiratory failure, and clinical outcomes. Results: Statistical correlations were identified between elevated NLR and PLR values and the development of complications during hospitalization (p = 0.04 and p = 0.00), acute hypoxemic respiratory failure (p = 0.00), and admission to the intensive care unit (ICU) (p = 0.04). No correlations were found between the values of these ratios and mortality (p = 0.46 and p = 0.32) nor with the development of hepatic cytolysis (p = 0.79 and p = 0.87). Conclusions: NLR and PLR are reliable, easily obtainable biomarkers that can aid in the early prediction of ICU admission and disease severity in COVID-19 patients, offering valuable insights for risk stratification and clinical management. Further prospective studies are needed to validate these biomarkers as part of a broader predictive model for critical care in COVID-19.
- Open Access
- 10 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 672
Novel Insights into CKMB, Myoglobin, and Troponin I Levels as Predictors of COVID-19 Severity and Hospitalization Outcomes
Background: COVID-19 has largely become an endemic disease in many regions, with sporadic outbreaks, with some areas where the disease shows a seasonal pattern like the influenza virus. The focus has shifted towards managing mild and moderate forms of disease through outpatient care, aiming to prevent healthcare system overload. Consequently, identifying markers that could be used in stratifying the risk and the prognostic assessment has become crucial. Cardiovascular implications of COVID-19 are a critical area of research due to their significant impact on disease severity, mortality, and morbidity. Methods: We conducted a retrospective, observational study and included 472 patients, diagnosed with COVID-19, all of whom were admitted to Prof. Dr. Matei Bals National Institute of Infectious Disease, Bucharest, Romania. Levels of cardiac biomarkers like creatine kinase (CK), creatine kinase-myocardial band (CKMB), myoglobin, troponins, and NT-pro-BNP were measured and analyzed in relation to clinical presentation and outcomes. Results: We combined CKMB, myoglobin, and troponin I to predict hospital length of stay (LOS). Our model significantly predicted LOS (F = 12.537, p = 0.0001), with higher levels associated with prolonged stays (β = 0.166, p = 0.000). Logistic regression demonstrated that the combination of elevated CKMB and myoglobin levels significantly increased the odds of a longer LOS (OR = 1.679, p = 0.000). Furthermore, we found significant correlations with acute respiratory failure (p = 0.001), severe forms of disease (p = 0.000), and the development of complications during hospitalization (p = 0.027). Conclusions: These findings emphasize the value of combining cardiac biomarkers to stratify risk and predict hospital outcomes in COVID-19 patients. Routine cardiac monitoring and targeted management strategies could decrease the risk of complications, reducing the LOS. Our findings highlight the potential of cardiac biomarkers as prognostic tools to stratify risk, guide clinical interventions, and improve outcomes in COVID-19 patients.
- 10 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 672
Open AccessNovel Insights into CKMB, Myoglobin, and Troponin I Levels as Predictors of COVID-19 Severity and Hospitalization Outcomes
Background: COVID-19 has largely become an endemic disease in many regions, with sporadic outbreaks, with some areas where the disease shows a seasonal pattern like the influenza virus. The focus has shifted towards managing mild and moderate forms of disease through outpatient care, aiming to prevent healthcare system overload. Consequently, identifying markers that could be used in stratifying the risk and the prognostic assessment has become crucial. Cardiovascular implications of COVID-19 are a critical area of research due to their significant impact on disease severity, mortality, and morbidity. Methods: We conducted a retrospective, observational study and included 472 patients, diagnosed with COVID-19, all of whom were admitted to Prof. Dr. Matei Bals National Institute of Infectious Disease, Bucharest, Romania. Levels of cardiac biomarkers like creatine kinase (CK), creatine kinase-myocardial band (CKMB), myoglobin, troponins, and NT-pro-BNP were measured and analyzed in relation to clinical presentation and outcomes. Results: We combined CKMB, myoglobin, and troponin I to predict hospital length of stay (LOS). Our model significantly predicted LOS (F = 12.537, p = 0.0001), with higher levels associated with prolonged stays (β = 0.166, p = 0.000). Logistic regression demonstrated that the combination of elevated CKMB and myoglobin levels significantly increased the odds of a longer LOS (OR = 1.679, p = 0.000). Furthermore, we found significant correlations with acute respiratory failure (p = 0.001), severe forms of disease (p = 0.000), and the development of complications during hospitalization (p = 0.027). Conclusions: These findings emphasize the value of combining cardiac biomarkers to stratify risk and predict hospital outcomes in COVID-19 patients. Routine cardiac monitoring and targeted management strategies could decrease the risk of complications, reducing the LOS. Our findings highlight the potential of cardiac biomarkers as prognostic tools to stratify risk, guide clinical interventions, and improve outcomes in COVID-19 patients.